

Table 1 Global death and YLL numbers, age-standardised rates per 100 000, and percentage change between 2007 and 2017 for both sexes combined for all GBD causes and Levels 1 through 4 of the cause hierarchy

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
All causes			55 945·7 (55 356·4 to 56 516·7)	9·3% (8·2 to 10·2)	737·7 (729·9 to 745·4)	–14·2% (–15·0 to –13·5)	1 646 249·6 (1 622 870·6 to 1 673 178·4)	–9·0% (–10·1 to –7·6)	21 926·4 (21 601·1 to 22 314·9)
Communicable, maternal, neonatal, and nutritional diseases			10 389·9 (10 004·0 to 10 975·9)	–22·2% (–24·0 to –20·0)	143·8 (138·4 to 151·6)	–31·8% (–33·3 to –30·1)	578 416·6 (558 815·0 to 600 759·1)	–30·4% (–32·4 to –28·2)	8280·6 (8005·4 to 8602·8)
	HIV/AIDS and sexually transmitted infections		1073·6 (983·3 to 1182·4)	–47·7% (–50·0 to –45·1)	13·9 (12·6 to 15·5)	–53·6% (–55·8 to –51·0)	60 550·2 (53 533·7 to 69 156·3)	–47·3% (–50·2 to –44·0)	806·4 (703·1 to 936·7)
	HIV/AIDS		954·5 (907·3 to 1009·7)	–50·3% (–52·1 to –48·3)	12·1 (11·5 to 12·9)	–56·5% (–58·0 to –54·7)	50 497·1 (47 658·0 to 53 595·8)	–51·2% (–52·9 to –49·2)	655·1 (617·5 to 696·4)
		HIV/AIDS and drug- susceptible tuberculosis co- infection	194·6 (137·7 to 253·0)	–55·4% (–58·4 to –51·6)	2·5 (1·8 to 3·2)	–61·1% (–63·7 to –57·7)	10 664·8 (7613·4 to 13 757·1)	–55·6% (–58·7 to –51·7)	140·0 (100·2 to 180·0)
		HIV/AIDS and multidrug-resistant tuberculosis without extensive drug resistance co- infection	22·6 (13·4 to 34·5)	–52·2% (–66·4 to –33·2)	0·3 (0·2 to 0·4)	–58·1% (–70·5 to –41·5)	1247·8 (746·6 to 1906·7)	–51·7% (–65·7 to –33·2)	16·4 (9·8 to 25·1)
		HIV/AIDS and extensively drug- resistant tuberculosis co-infection	1·2 (0·8 to 1·8)	–8·3% (–26·8 to 14·7)	0·0 (0·0 to 0·0)	–20·3% (–36·4 to –0·2)	62·7 (38·3 to 92·9)	–10·5% (–28·4 to 11·5)	0·8 (0·5 to 1·2)
		HIV/AIDS resulting in other diseases	736·0 (659·5 to 817·7)	–48·7% (–51·1 to –45·9)	9·3 (8·4 to 10·4)	–55·1% (–57·2 to –52·6)	38 521·8 (34 381·3 to 43 095·5)	–49·8% (–52·3 to –46·9)	497·9 (444·2 to 558·4)
	Sexually transmitted infections excluding HIV		119·1 (50·8 to 220·4)	–10·8% (–18·4 to –2·5)	1·8 (0·7 to 3·3)	–14·4% (–21·5 to –6·6)	10 053·1 (4057·0 to 18 915·2)	–11·4% (–19·0 to –3·2)	151·3 (60·6 to 285·3)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Syphilis	113·5 (45·2 to 214·5)	–11·3% (–19·1 to –2·8)	1·7 (0·7 to 3·2)	–14·3% (–21·8 to –6·4)	9836·1 (3848·5 to 18 676·4)	–11·5% (–19·3 to –3·1)	148·6 (58·0 to 282·3)
		Chlamydial infection	1·1 (0·9 to 1·2)	2·5% (–4·5 to 11·3)	0·0 (0·0 to 0·0)	–15·2% (–21·0 to –8·4)	40·5 (32·6 to 45·0)	–5·5% (–12·2 to 2·5)	0·5 (0·4 to 0·6)
		Gonococcal infection	3·0 (2·4 to 3·3)	3·7% (–3·4 to 12·5)	0·0 (0·0 to 0·0)	–14·9% (–20·8 to –8·2)	112·8 (90·2 to 124·9)	–3·8% (–10·7 to 4·3)	1·4 (1·1 to 1·6)
		Other sexually transmitted infections	1·5 (1·2 to 1·7)	0·2% (–6·4 to 8·3)	0·0 (0·0 to 0·0)	–15·9% (–21·6 to –9·5)	63·6 (51·0 to 70·7)	–6·2% (–12·7 to 1·1)	0·8 (0·6 to 0·9)
	Respiratory infections and tuberculosis		3752·3 (3629·4 to 3889·3)	–8·0% (–10·3 to –5·5)	50·5 (48·8 to 52·3)	–24·5% (–26·4 to –22·6)	148 233·5 (141 335·1 to 155 291·4)	–24·7% (–27·4 to –21·7)	2056·0 (1956·3 to 2160·7)
	Tuberculosis		1183·7 (1129·8 to 1245·3)	–14·9% (–18·2 to –10·3)	14·9 (14·3 to 15·7)	–31·4% (–34·1 to –27·6)	41 876·9 (39 972·4 to 44 120·5)	–21·2% (–24·4 to –17·4)	533·4 (509·1 to 562·6)
		Drug-susceptible tuberculosis	1044·1 (951·6 to 1129·2)	–15·5% (–22·3 to –8·6)	13·2 (12·0 to 14·2)	–31·9% (–37·3 to –26·4)	36 932·5 (33 846·8 to 39 919·1)	–21·9% (–27·8 to –16·0)	470·7 (431·3 to 508·4)
		Multidrug-resistant tuberculosis without extensive drug resistance	126·9 (70·1 to 202·2)	–11·6% (–47·4 to 38·1)	1·6 (0·9 to 2·5)	–28·6% (–57·4 to 11·4)	4505·1 (2582·5 to 6984·6)	–17·6% (–49·4 to 26·5)	57·2 (33·0 to 88·4)
		Extensively drug- resistant tuberculosis	12·6 (8·6 to 18·0)	14·0% (–18·7 to 58·7)	0·2 (0·1 to 0·2)	–7·7% (–34·1 to 28·8)	439·2 (306·2 to 616·5)	5·5% (–23·2 to 44·9)	5·5 (3·8 to 7·7)
	Lower respiratory infections		2558·6 (2442·2 to 2655·4)	–4·3% (–6·9 to –1·5)	35·4 (33·8 to 36·8)	–21·1% (–23·2 to –18·9)	105 834·5 (99 746·4 to 111 767·8)	–25·9% (–29·2 to –22·2)	1515·1 (1424·8 to 1602·2)
	Upper respiratory infections		9·1 (6·1 to 12·4)	–30·5% (–41·0 to –14·5)	0·1 (0·1 to 0·2)	–42·1% (–49·6 to –29·9)	477·3 (247·3 to 730·5)	–33·2% (–44·1 to –12·9)	6·9 (3·5 to 10·6)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Otitis media		0·9 (0·7 to 1·5)	–41·4% (–51·6 to –28·4)	0·0 (0·0 to 0·0)	–50·4% (–58·8 to –39·9)	44·8 (31·2 to 72·1)	–49·4% (–59·9 to –35·5)	0·6 (0·4 to 1·0)
	Enteric infections		1766·0 (1398·0 to 2386·0)	–17·2% (–24·6 to –8·2)	24·4 (19·5 to 32·4)	–29·9% (–34·9 to –23·1)	84 625·5 (73 770·6 to 100 720·2)	–30·6% (–36·3 to –23·7)	1208·6 (1064·1 to 1424·7)
	Diarrhoeal diseases		1569·6 (1176·0 to 2193·0)	–16·6% (–25·3 to –6·7)	21·6 (16·4 to 29·7)	–30·2% (–36·1 to –22·7)	70 574·3 (60 421·1 to 86 165·2)	–32·0% (–38·6 to –23·9)	1009·1 (870·5 to 1211·0)
	Typhoid and paratyphoid		135·9 (76·9 to 218·9)	–22·3% (–27·3 to –18·1)	1·9 (1·1 to 3·0)	–27·8% (–32·8 to –23·9)	9686·1 (5484·9 to 15 746·2)	–23·8% (–29·3 to –19·4)	136·3 (77·0 to 220·9)
		Typhoid fever	116·8 (65·4 to 187·7)	–23·7% (–29·0 to –19·3)	1·6 (0·9 to 2·6)	–29·1% (–34·1 to –25·0)	8331·7 (4632·5 to 13 419·2)	–25·3% (–31·0 to –20·8)	117·3 (65·5 to 188·5)
		Paratyphoid fever	19·1 (8·7 to 37·3)	–12·7% (–20·1 to –4·2)	0·3 (0·1 to 0·5)	–18·9% (–26·1 to –10·8)	1354·4 (622·3 to 2620·2)	–13·2% (–21·3 to –3·8)	19·0 (8·8 to 36·6)
	Invasive non-typhoidal salmonella		59·1 (33·3 to 98·1)	–17·9% (–25·1 to –8·7)	0·8 (0·5 to 1·4)	–24·8% (–31·9 to –15·6)	4260·8 (2382·0 to 7378·6)	–17·2% (–25·7 to –6·8)	61·6 (34·7 to 107·6)
	Other intestinal infectious diseases		1·4 (1·0 to 2·2)	–39·7% (–67·1 to 9·7)	0·0 (0·0 to 0·0)	–44·7% (–70·1 to 2·3)	104·4 (67·8 to 170·7)	–43·6% (–71·6 to 11·9)	1·5 (1·0 to 2·5)
	Neglected tropical diseases and malaria		720·1 (530·7 to 938·8)	–29·0% (–37·3 to –19·3)	10·1 (7·5 to 13·2)	–36·1% (–43·7 to –27·3)	48 656·2 (35 574·6 to 64 934·2)	–33·7% (–42·4 to –23·7)	699·9 (508·0 to 933·6)
	Malaria		619·8 (440·1 to 839·5)	–30·8% (–39·4 to –20·8)	8·7 (6·1 to 11·9)	–37·3% (–45·4 to –27·9)	43 546·6 (29 966·3 to 59 772·4)	–34·5% (–43·8 to –23·6)	629·4 (432·6 to 858·7)
	Chagas disease		7·9 (7·5 to 8·6)	3·8% (–1·6 to 12·9)	0·1 (0·1 to 0·1)	–21·1% (–25·2 to –14·3)	174·9 (166·1 to 193·5)	–4·2% (–9·0 to 4·8)	2·2 (2·0 to 2·4)
	Leishmaniasis		7·5 (0·0 to 34·5)	–64·8% (–96·8 to –44·5)	0·1 (0·0 to 0·5)	–67·8% (–97·5 to –50·3)	509·8 (0·3 to 2440·2)	–63·8% (–92·1 to –39·7)	7·2 (0·0 to 34·6)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Visceral leishmaniasis	7·5 (0·0 to 34·5)	–64·8% (–96·8 to –44·5)	0·1 (0·0 to 0·5)	–67·8% (–97·5 to –50·3)	509·8 (0·3 to 2440·2)	–63·8% (–92·1 to –39·7)	7·2 (0·0 to 34·6)
	African trypanosomiasis		1·4 (0·3 to 4·9)	–80·7% (–95·6 to –27·8)	0·0 (0·0 to 0·1)	–82·8% (–96·0 to –34·3)	77·6 (15·0 to 283·6)	–80·8% (–95·6 to –27·2)	1·0 (0·2 to 3·8)
	Schistosomiasis		8·8 (8·0 to 9·8)	–12·3% (–17·6 to –6·4)	0·1 (0·1 to 0·1)	–28·5% (–32·7 to –23·7)	342·3 (305·3 to 384·3)	–15·6% (–21·9 to –8·8)	4·4 (3·9 to 5·0)
	Cysticercosis		0·7 (0·5 to 1·0)	–15·9% (–42·7 to 23·3)	0·0 (0·0 to 0·0)	–27·3% (–50·5 to 5·3)	39·6 (26·9 to 55·0)	–20·5% (–46·9 to 18·2)	0·5 (0·4 to 0·7)
	Cystic echinococcosis		1·2 (0·9 to 1·5)	–30·0% (–52·1 to –1·3)	0·0 (0·0 to 0·0)	–41·9% (–59·8 to –19·0)	52·0 (38·1 to 68·0)	–38·8% (–56·8 to –12·9)	0·7 (0·5 to 0·9)
	Dengue		40·5 (17·6 to 49·8)	65·5% (21·7 to 99·7)	0·5 (0·2 to 0·7)	40·7% (3·6 to 69·7)	1902·9 (716·6 to 2312·9)	32·0% (–1·8 to 61·2)	26·1 (9·8 to 31·7)
	Yellow fever		4·8 (1·0 to 13·8)	–16·6% (–28·7 to –2·0)	0·1 (0·0 to 0·2)	–23·3% (–34·4 to –9·6)	313·9 (67·2 to 900·2)	–16·0% (–28·9 to 0·0)	4·3 (0·9 to 12·4)
	Rabies		11·7 (9·3 to 14·7)	–48·1% (–58·8 to –37·3)	0·2 (0·1 to 0·2)	–54·8% (–63·8 to –45·0)	633·7 (504·4 to 836·4)	–51·5% (–61·3 to –38·9)	8·6 (6·8 to 11·5)
	Intestinal nematode infections		3·2 (2·5 to 4·1)	–43·1% (–56·1 to –25·0)	0·0 (0·0 to 0·1)	–47·2% (–59·5 to –30·1)	257·1 (194·1 to 336·3)	–44·1% (–57·6 to –25·0)	3·8 (2·9 to 5·0)
		Ascariasis	3·2 (2·5 to 4·1)	–43·1% (–56·1 to –25·0)	0·0 (0·0 to 0·1)	–47·2% (–59·5 to –30·1)	257·1 (194·1 to 336·3)	–44·1% (–57·6 to –25·0)	3·8 (2·9 to 5·0)
	Ebola virus disease		0·0 (0·0 to 0·0)	–98·2% (–98·4 to –98·0)	0·0 (0·0 to 0·0)	–98·4% (–98·6 to –98·2)	0·5 (0·5 to 0·5)	–98·1% (–98·3 to –97·9)	0·0 (0·0 to 0·0)
	Zika virus disease		0·0 (0·0 to 0·1)	..	0·0 (0·0 to 0·0)	..	1·0 (0·2 to 3·4)	..	0·0 (0·0 to 0·0)
	Other neglected tropical diseases		12·6 (8·0 to 36·3)	8·1% (–8·1 to 28·2)	0·2 (0·1 to 0·5)	–3·7% (–18·3 to 13·9)	804·3 (442·8 to 2696·6)	3·9% (–16·3 to 29·4)	11·6 (6·3 to 39·6)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Other infectious diseases		830·5 (732·2 to 947·8)	–25·9% (–32·4 to –18·8)	11·6 (10·1 to 13·3)	–33·8% (–39·3 to –27·4)	53 008·6 (44 786·0 to 63 000·4)	–33·0% (–39·6 to –25·1)	762·8 (640·5 to 911·5)
	Meningitis		288·0 (254·3 to 333·2)	–20·1% (–26·0 to –11·0)	4·0 (3·6 to 4·6)	–27·8% (–33·1 to –19·3)	19 436·9 (16 935·1 to 22 335·8)	–25·2% (–31·5 to –15·7)	280·5 (243·6 to 323·2)
		Pneumococcal meningitis	42·1 (36·6 to 49·4)	–13·4% (–20·6 to –2·3)	0·6 (0·5 to 0·7)	–22·4% (–28·9 to –12·4)	2751·8 (2325·8 to 3276·5)	–18·5% (–26·8 to –6·5)	39·6 (33·4 to 47·0)
		<i>H influenzae</i> type B meningitis	75·7 (66·7 to 92·0)	–33·7% (–39·6 to –26·0)	1·1 (0·9 to 1·3)	–40·6% (–45·8 to –33·9)	4907·3 (4232·2 to 5813·6)	–40·4% (–46·1 to –33·0)	70·5 (60·6 to 83·9)
		Meningococcal infection	30·0 (25·7 to 35·7)	–31·5% (–37·4 to –22·8)	0·4 (0·4 to 0·5)	–37·1% (–42·6 to –29·2)	2180·3 (1819·8 to 2614·5)	–34·9% (–41·4 to –26·4)	31·9 (26·5 to 38·4)
		Other meningitis	140·3 (121·4 to 161·8)	–8·9% (–15·4 to 1·4)	2·0 (1·7 to 2·3)	–17·3% (–23·4 to –7·5)	9597·5 (8195·6 to 11 118·5)	–12·8% (–20·4 to –0·7)	138·5 (118·3 to 160·5)
	Encephalitis		92·4 (83·1 to 107·9)	0·0% (–14·2 to 16·2)	1·2 (1·1 to 1·4)	–14·3% (–26·5 to –0·9)	4588·2 (4059·5 to 5230·7)	–12·1% (–28·1 to 4·5)	64·1 (56·6 to 72·4)
	Diphtheria		3·6 (2·2 to 6·1)	–23·9% (–55·6 to 36·4)	0·1 (0·0 to 0·1)	–28·6% (–58·8 to 29·2)	298·7 (181·8 to 510·0)	–23·9% (–56·7 to 38·7)	4·4 (2·7 to 7·6)
	Whooping cough		91·8 (45·9 to 163·2)	–23·3% (–54·8 to 35·6)	1·4 (0·7 to 2·4)	–27·1% (–57·1 to 28·8)	7879·2 (3938·1 to 14 010·3)	–23·3% (–54·8 to 35·4)	117·9 (58·9 to 209·6)
	Tetanus		38·1 (25·9 to 48·8)	–54·9% (–65·9 to –39·1)	0·5 (0·4 to 0·7)	–59·6% (–69·3 to –45·0)	2447·7 (1734·9 to 3199·0)	–59·3% (–69·9 to –43·5)	35·1 (25·0 to 46·3)
	Measles		95·3 (34·5 to 205·2)	–57·0% (–61·9 to –51·9)	1·4 (0·5 to 3·1)	–59·3% (–64·0 to –54·4)	8105·1 (2935·7 to 17 469·0)	–56·9% (–61·8 to –51·8)	120·8 (43·7 to 260·4)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Varicella and herpes zoster		15·6 (14·4 to 17·3)	–16·4% (–22·9 to –9·5)	0·2 (0·2 to 0·2)	–29·2% (–34·7 to –23·4)	833·0 (742·3 to 938·1)	–22·5% (–31·4 to –13·2)	12·1 (10·7 to 13·6)
	Acute hepatitis		126·4 (94·5 to 143·7)	–9·8% (–15·5 to –2·3)	1·6 (1·2 to 1·9)	–24·5% (–29·2 to –18·4)	5478·4 (4040·3 to 6330·0)	–21·7% (–27·7 to –14·4)	72·3 (52·9 to 83·9)
		Acute hepatitis A	18·6 (13·6 to 23·8)	–33·1% (–41·9 to –22·5)	0·3 (0·2 to 0·3)	–38·7% (–46·8 to –28·6)	1286·7 (935·2 to 1633·7)	–36·0% (–45·1 to –24·3)	18·0 (13·0 to 22·9)
		Acute hepatitis B	89·6 (66·1 to 102·5)	–0·8% (–8·4 to 8·5)	1·1 (0·8 to 1·3)	–19·6% (–25·4 to –12·4)	3262·4 (2367·8 to 3819·1)	–12·2% (–19·7 to –2·7)	41·8 (30·1 to 49·3)
		Acute hepatitis C	3·5 (1·9 to 6·0)	–23·7% (–35·9 to –9·4)	0·0 (0·0 to 0·1)	–32·1% (–42·4 to –19·6)	219·7 (120·1 to 371·3)	–31·0% (–43·3 to –15·3)	3·2 (1·8 to 5·4)
		Acute hepatitis E	14·7 (10·4 to 18·5)	–15·8% (–27·2 to –3·1)	0·2 (0·1 to 0·2)	–25·8% (–35·3 to –15·6)	709·6 (489·6 to 903·9)	–25·5% (–35·2 to –14·5)	9·3 (6·4 to 11·8)
	Other unspecified infectious diseases		79·3 (59·9 to 85·1)	1·6% (–3·1 to 7·9)	1·1 (0·8 to 1·2)	–13·4% (–17·5 to –8·1)	3941·3 (2831·7 to 4325·8)	–10·2% (–16·2 to –2·4)	55·6 (39·6 to 61·3)
	Maternal and neonatal disorders		1977·4 (1890·1 to 2060·6)	–24·1% (–26·9 to –21·0)	29·5 (28·2 to 30·8)	–26·6% (–29·3 to –23·5)	167 684·6 (160 060·7 to 174 918·2)	–24·2% (–27·1 to –20·9)	2518·2 (2403·8 to 2627·1)
	Maternal disorders		193·6 (179·9 to 209·6)	–24·0% (–28·4 to –19·5)	2·5 (2·3 to 2·7)	–30·7% (–34·8 to –26·6)	10 993·1 (10 198·9 to 11 928·5)	–25·3% (–29·7 to –20·9)	140·9 (130·8 to 153·0)
		Maternal haemorrhage	38·5 (33·2 to 45·2)	–52·1% (–59·0 to –44·2)	0·5 (0·4 to 0·6)	–56·4% (–62·7 to –49·3)	2173·8 (1859·7 to 2552·5)	–53·0% (–60·1 to –45·0)	27·8 (23·8 to 32·7)
		Maternal sepsis and other pregnancy-related infections	21·2 (18·2 to 25·0)	–27·1% (–38·8 to –15·1)	0·3 (0·2 to 0·3)	–33·5% (–44·2 to –22·6)	1198·0 (1022·8 to 1420·8)	–28·9% (–41·1 to –16·2)	15·4 (13·1 to 18·3)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Maternal hypertensive disorders	29·4 (25·4 to 34·5)	–5·5% (–20·7 to 11·2)	0·4 (0·3 to 0·4)	–13·0% (–27·3 to 2·6)	1729·6 (1487·6 to 2033·2)	–6·6% (–22·1 to 10·2)	22·3 (19·2 to 26·4)
		Maternal obstructed labour and uterine rupture	13·0 (10·2 to 16·8)	–17·7% (–35·9 to 2·9)	0·2 (0·1 to 0·2)	–25·2% (–41·0 to –6·3)	720·9 (565·5 to 946·4)	–18·9% (–37·6 to 1·9)	9·2 (7·2 to 12·1)
		Maternal abortive outcome	17·4 (14·7 to 20·8)	–7·0% (–22·3 to 10·1)	0·2 (0·2 to 0·3)	–15·7% (–29·3 to –0·4)	963·4 (807·6 to 1161·1)	–8·9% (–24·2 to 8·7)	12·3 (10·3 to 14·9)
		Ectopic pregnancy	10·2 (7·1 to 15·2)	–11·6% (–41·4 to 27·9)	0·1 (0·1 to 0·2)	–19·2% (–46·2 to 16·8)	590·6 (409·0 to 881·4)	–13·3% (–43·8 to 26·9)	7·6 (5·3 to 11·4)
		Indirect maternal deaths	34·1 (30·0 to 38·7)	–4·1% (–16·7 to 8·5)	0·4 (0·4 to 0·5)	–12·5% (–24·0 to –1·0)	1934·4 (1694·2 to 2216·7)	–6·1% (–19·2 to 6·8)	24·8 (21·7 to 28·5)
		Late maternal deaths	3·4 (2·6 to 4·3)	–0·9% (–7·0 to 5·5)	0·0 (0·0 to 0·1)	–9·5% (–14·7 to –4·0)	194·7 (152·2 to 251·4)	–2·0% (–8·2 to 4·1)	2·5 (2·0 to 3·2)
		Maternal deaths aggravated by HIV/AIDS	1·6 (1·0 to 2·1)	–23·9% (–31·0 to –16·0)	0·0 (0·0 to 0·0)	–32·1% (–38·4 to –25·2)	84·4 (53·0 to 113·8)	–26·7% (–33·6 to –19·2)	1·1 (0·7 to 1·4)
		Other maternal disorders	24·8 (20·8 to 29·8)	–8·5% (–24·7 to 11·2)	0·3 (0·3 to 0·4)	–16·5% (–31·2 to 1·5)	1403·1 (1159·5 to 1690·3)	–9·8% (–26·7 to 10·8)	18·0 (14·9 to 21·7)
	Neonatal disorders		1783·8 (1698·5 to 1864·7)	–24·1% (–27·2 to –20·6)	27·1 (25·8 to 28·3)	–26·2% (–29·1 to –22·7)	156 691·6 (149 207·2 to 163 802·2)	–24·1% (–27·2 to –20·6)	2377·2 (2263·7 to 2485·1)
		Neonatal preterm birth	649·4 (605·4 to 721·3)	–26·2% (–31·3 to –21·5)	9·9 (9·2 to 10·9)	–28·1% (–33·2 to –23·6)	57 052·0 (53 182·3 to 63 367·1)	–26·2% (–31·3 to –21·5)	865·6 (806·9 to 961·5)
		Neonatal encephalopathy due to birth asphyxia and trauma	533·3 (476·9 to 580·3)	–24·5% (–30·2 to –18·0)	8·1 (7·2 to 8·8)	–26·5% (–32·0 to –20·2)	46 845·9 (41 894·1 to 50 985·7)	–24·5% (–30·2 to –18·0)	710·8 (635·7 to 773·7)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Neonatal sepsis and other neonatal infections	203·0 (178·7 to 267·1)	–11·9% (–20·5 to –1·7)	3·1 (2·7 to 4·1)	–14·4% (–22·7 to –4·4)	17 830·7 (15 692·9 to 23 459·0)	–11·9% (–20·5 to –1·7)	270·4 (238·0 to 355·8)
		Haemolytic disease and other neonatal jaundice	49·1 (42·9 to 55·9)	–37·5% (–45·3 to –28·2)	0·7 (0·7 to 0·8)	–39·3% (–46·8 to –30·2)	4309·1 (3771·2 to 4914·0)	–37·5% (–45·3 to –28·2)	65·4 (57·2 to 74·5)
		Other neonatal disorders	349·0 (294·9 to 382·3)	–23·6% (–29·8 to –15·5)	5·3 (4·5 to 5·8)	–25·7% (–31·7 to –17·8)	30 654·0 (25 899·7 to 33 578·7)	–23·6% (–29·8 to –15·5)	465·0 (392·9 to 509·4)
	Nutritional deficiencies		270·0 (249·3 to 295·5)	–23·9% (–29·2 to –15·7)	3·8 (3·5 to 4·2)	–33·6% (–38·1 to –26·5)	15 658·0 (14 051·5 to 17 506·6)	–34·7% (–40·5 to –26·1)	228·7 (204·9 to 255·9)
	Protein-energy malnutrition		231·8 (212·4 to 254·2)	–26·1% (–31·7 to –17·9)	3·3 (3·0 to 3·7)	–34·6% (–39·4 to –27·5)	14 405·4 (12 873·5 to 16 128·0)	–35·1% (–41·1 to –26·7)	211·8 (189·0 to 237·3)
	Other nutritional deficiencies		38·2 (33·7 to 44·6)	–7·2% (–14·6 to 3·1)	0·5 (0·4 to 0·6)	–25·8% (–31·7 to –17·5)	1252·7 (1087·5 to 1435·2)	–29·2% (–36·9 to –19·7)	16·9 (14·6 to 19·5)
Non-communicable diseases			41 071·1 (40 470·9 to 41 548·9)	22·7% (21·5 to 23·9)	536·1 (528·4 to 542·2)	–7·9% (–8·8 to –7·0)	872 601·8 (859 538·6 to 884 787·7)	13·6% (12·2 to 14·9)	11 097·4 (10 928·6 to 11 253·8)
	Neoplasms		9556·2 (9395·7 to 9692·3)	25·4% (23·9 to 27·0)	121·2 (119·1 to 122·9)	–4·4% (–5·6 to –3·3)	225 738·1 (221 608·8 to 229 322·4)	19·6% (17·8 to 21·4)	2803·4 (2751·5 to 2848·8)
	Lip and oral cavity cancer		193·7 (184·7 to 201·6)	35·6% (29·5 to 40·8)	2·4 (2·3 to 2·5)	4·0% (–0·6 to 8·0)	5090·6 (4819·5 to 5328·3)	30·5% (23·8 to 36·4)	62·2 (58·9 to 65·1)
	Nasopharynx cancer		69·5 (66·9 to 72·3)	24·4% (20·0 to 28·8)	0·9 (0·8 to 0·9)	–3·0% (–6·4 to 0·4)	2034·5 (1954·7 to 2117·4)	18·3% (13·9 to 23·1)	24·8 (23·8 to 25·8)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Other pharynx cancer		117·4 (102·1 to 124·5)	40·4% (29·7 to 48·4)	1·4 (1·3 to 1·5)	7·9% (–0·3 to 14·0)	3204·2 (2766·3 to 3405·1)	36·0% (25·4 to 44·2)	38·9 (33·5 to 41·3)
	Oesophageal cancer		436·0 (425·0 to 447·6)	13·0% (9·9 to 16·3)	5·5 (5·3 to 5·6)	–14·5% (–16·9 to –12·0)	9647·5 (9410·7 to 9903·5)	8·9% (5·8 to 12·2)	118·3 (115·4 to 121·4)
	Stomach cancer		865·0 (848·3 to 884·7)	9·4% (7·1 to 12·1)	11·0 (10·8 to 11·2)	–17·1% (–18·8 to –15·1)	18 782·0 (18 409·7 to 19 207·7)	4·8% (2·4 to 7·4)	231·6 (227·0 to 236·8)
	Colon and rectum cancer		896·0 (876·3 to 915·7)	27·8% (24·0 to 31·3)	11·5 (11·3 to 11·8)	–4·3% (–7·1 to –1·8)	18 106·7 (17 678·0 to 18 525·0)	23·8% (19·2 to 27·6)	224·7 (219·4 to 229·9)
	Liver cancer		819·4 (789·7 to 855·5)	27·0% (23·0 to 32·9)	10·2 (9·8 to 10·7)	–2·5% (–5·6 to 2·0)	20 536·2 (19 678·7 to 21 551·9)	21·2% (17·0 to 27·4)	250·7 (240·4 to 263·0)
		Liver cancer due to hepatitis B	325·4 (304·6 to 348·2)	20·3% (15·3 to 28·2)	4·0 (3·7 to 4·3)	–6·2% (–10·0 to 0·1)	9449·0 (8837·3 to 10 138·6)	14·7% (9·7 to 21·9)	114·6 (107·3 to 123·0)
		Liver cancer due to hepatitis C	234·3 (219·4 to 250·6)	30·4% (26·7 to 35·0)	3·0 (2·8 to 3·2)	–2·1% (–4·9 to 1·4)	4898·4 (4554·0 to 5259·3)	26·9% (23·3 to 31·6)	60·3 (56·2 to 64·7)
		Liver cancer due to alcohol use	129·3 (114·5 to 147·3)	31·7% (26·8 to 37·3)	1·6 (1·4 to 1·8)	0·6% (–3·0 to 4·8)	3040·7 (2647·6 to 3549·8)	27·8% (22·4 to 33·9)	37·2 (32·5 to 43·3)
		Liver cancer due to NASH	66·9 (59·6 to 74·5)	42·3% (38·0 to 47·6)	0·8 (0·8 to 0·9)	7·6% (4·4 to 11·7)	1443·8 (1288·9 to 1605·9)	37·3% (32·7 to 42·8)	17·8 (15·9 to 19·7)
		Liver cancer due to other causes	63·5 (57·4 to 70·6)	28·2% (23·6 to 34·3)	0·8 (0·7 to 0·9)	–0·9% (–4·2 to 3·6)	1704·2 (1528·4 to 1903·8)	21·1% (16·0 to 27·4)	20·9 (18·8 to 23·3)
	Gallbladder and biliary tract cancer		174·0 (154·2 to 184·9)	25·0% (21·5 to 28·7)	2·2 (2·0 to 2·4)	–6·7% (–9·4 to –4·0)	3434·0 (3009·7 to 3660·0)	21·8% (17·8 to 26·3)	42·6 (37·3 to 45·4)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Pancreatic cancer		441·1 (432·8 to 449·0)	39·9% (36·7 to 42·6)	5·6 (5·5 to 5·7)	4·8% (2·5 to 6·8)	8988·1 (8806·6 to 9162·9)	35·8% (32·5 to 38·6)	111·1 (108·9 to 113·2)
	Larynx cancer		126·5 (123·4 to 129·9)	21·1% (17·8 to 24·4)	1·6 (1·5 to 1·6)	–7·7% (–10·1 to –5·2)	3170·0 (3089·7 to 3260·3)	17·3% (13·9 to 20·9)	38·5 (37·6 to 39·6)
	Tracheal, bronchus, and lung cancer		1883·1 (1844·2 to 1922·8)	29·6% (26·5 to 32·5)	23·7 (23·3 to 24·2)	–2·0% (–4·3 to 0·1)	40 391·6 (39 506·7 to 41 285·6)	24·8% (21·7 to 27·6)	496·4 (485·5 to 507·2)
	Malignant skin melanoma		61·7 (47·9 to 70·3)	23·6% (19·0 to 26·9)	0·8 (0·6 to 0·9)	–5·1% (–8·5 to –2·5)	1513·2 (1220·7 to 1774·4)	16·1% (12·7 to 20·0)	18·7 (15·1 to 21·9)
	Non-melanoma skin cancer		65·1 (63·1 to 66·5)	38·6% (34·9 to 41·2)	0·8 (0·8 to 0·9)	2·7% (0·0 to 4·5)	1239·1 (1200·2 to 1266·6)	30·0% (26·2 to 32·7)	15·5 (15·0 to 15·8)
		Non-melanoma skin cancer (squamous- cell carcinoma)	65·1 (63·1 to 66·5)	38·6% (34·9 to 41·2)	0·8 (0·8 to 0·9)	2·7% (0·0 to 4·5)	1239·1 (1200·2 to 1266·6)	30·0% (26·2 to 32·7)	15·5 (15·0 to 15·8)
	Breast cancer		611·6 (589·2 to 640·7)	27·0% (21·3 to 31·2)	7·6 (7·4 to 8·0)	–2·6% (–6·9 to 0·4)	16 400·7 (15 737·0 to 17 320·2)	23·9% (17·3 to 28·7)	200·2 (192·1 to 211·4)
	Cervical cancer		259·7 (241·1 to 269·2)	18·8% (12·9 to 22·8)	3·2 (3·0 to 3·3)	–7·2% (–11·7 to –4·0)	7773·5 (7227·4 to 8087·8)	15·1% (9·4 to 19·1)	94·6 (88·1 to 98·5)
	Uterine cancer		85·2 (83·2 to 87·4)	18·8% (15·8 to 22·5)	1·1 (1·0 to 1·1)	–10·4% (–12·5 to –7·7)	1930·0 (1879·9 to 1983·0)	14·8% (11·6 to 19·0)	23·7 (23·1 to 24·3)
	Ovarian cancer		176·0 (171·4 to 181·2)	30·3% (26·8 to 33·7)	2·2 (2·1 to 2·3)	–1·0% (–3·6 to 1·6)	4496·9 (4370·7 to 4642·1)	29·1% (24·8 to 33·1)	54·9 (53·4 to 56·7)
	Prostate cancer		415·9 (357·3 to 489·5)	32·5% (29·3 to 38·4)	5·5 (4·7 to 6·5)	–2·5% (–4·9 to 1·9)	6214·5 (5324·2 to 7293·0)	28·3% (24·9 to 34·5)	79·3 (68·1 to 93·0)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Testicular cancer		7·7 (7·4 to 8·0)	6·1% (2·3 to 10·9)	0·1 (0·1 to 0·1)	–9·4% (–12·6 to –5·2)	338·7 (323·8 to 357·4)	0·9% (–3·3 to 6·3)	4·3 (4·1 to 4·5)
	Kidney cancer		138·5 (128·7 to 142·5)	30·1% (26·2 to 34·1)	1·8 (1·6 to 1·8)	–1·3% (–4·3 to 1·7)	3143·3 (2952·2 to 3234·1)	23·1% (18·5 to 27·3)	39·4 (37·0 to 40·5)
	Bladder cancer		196·5 (191·5 to 205·8)	27·8% (25·1 to 30·4)	2·6 (2·5 to 2·7)	–5·4% (–7·3 to –3·4)	3350·1 (3257·4 to 3511·6)	22·6% (19·9 to 25·3)	42·2 (41·0 to 44·1)
	Brain and nervous system cancer		247·1 (213·0 to 265·0)	29·2% (23·2 to 33·4)	3·1 (2·7 to 3·3)	3·8% (–1·0 to 7·0)	8577·8 (7527·0 to 9359·3)	18·4% (11·9 to 24·6)	109·8 (96·1 to 120·0)
	Thyroid cancer		41·2 (39·9 to 44·1)	28·9% (24·3 to 33·3)	0·5 (0·5 to 0·6)	–1·2% (–4·5 to 2·0)	1001·2 (963·6 to 1074·0)	22·1% (16·7 to 28·0)	12·4 (12·0 to 13·4)
	Mesothelioma		29·9 (29·1 to 30·6)	26·9% (20·1 to 32·6)	0·4 (0·4 to 0·4)	–3·4% (–8·4 to 0·7)	655·7 (635·2 to 677·0)	21·0% (13·8 to 27·3)	8·1 (7·9 to 8·4)
	Hodgkin lymphoma		32·6 (27·6 to 38·1)	0·2% (–3·5 to 3·6)	0·4 (0·4 to 0·5)	–16·8% (–19·8 to –14·0)	1327·6 (1110·1 to 1567·7)	–5·2% (–8·6 to –1·8)	17·1 (14·3 to 20·2)
	Non-Hodgkin lymphoma		248·6 (243·5 to 253·1)	29·4% (25·5 to 32·4)	3·2 (3·1 to 3·2)	0·1% (–2·7 to 2·4)	6828·8 (6611·8 to 7020·0)	22·1% (15·6 to 26·9)	86·8 (84·0 to 89·5)
	Multiple myeloma		107·1 (98·5 to 118·9)	32·7% (28·4 to 36·4)	1·4 (1·3 to 1·5)	–0·4% (–3·5 to 2·4)	2234·7 (2091·4 to 2493·2)	30·4% (25·6 to 34·4)	27·7 (25·9 to 30·8)
	Leukaemia		347·6 (317·3 to 364·9)	12·8% (9·5 to 15·6)	4·5 (4·1 to 4·7)	–9·6% (–12·2 to –7·4)	11 712·0 (10 531·4 to 12 523·3)	2·3% (–3·7 to 6·2)	153·4 (137·9 to 164·5)
		Acute lymphoid leukaemia	52·2 (46·0 to 56·7)	14·1% (2·6 to 23·2)	0·7 (0·6 to 0·7)	–1·5% (–11·6 to 6·2)	2661·7 (2341·7 to 2941·1)	5·3% (–8·6 to 15·4)	36·1 (31·7 to 40·0)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Chronic lymphoid leukaemia	35·2 (33·5 to 36·9)	21·4% (17·7 to 25·0)	0·5 (0·4 to 0·5)	–10·3% (–13·0 to –7·6)	634·1 (595·7 to 674·2)	18·3% (14·2 to 22·4)	8·0 (7·5 to 8·5)
		Acute myeloid leukaemia	99·9 (91·3 to 104·6)	24·6% (17·1 to 29·8)	1·3 (1·2 to 1·3)	–1·0% (–6·6 to 3·0)	3192·6 (2868·8 to 3405·6)	16·2% (4·4 to 24·6)	41·3 (37·0 to 44·1)
		Chronic myeloid leukaemia	24·1 (22·2 to 26·1)	3·3% (0·4 to 6·4)	0·3 (0·3 to 0·3)	–19·9% (–22·2 to –17·6)	643·3 (583·4 to 699·1)	–1·7% (–5·2 to 1·5)	8·0 (7·3 to 8·7)
		Other leukaemia	136·2 (121·0 to 146·8)	4·9% (0·9 to 9·7)	1·8 (1·6 to 1·9)	–15·6% (–18·7 to –12·1)	4580·2 (3955·1 to 5013·3)	–8·1% (–14·6 to –1·8)	60·0 (51·9 to 65·7)
	Other malignant cancers		359·5 (331·4 to 370·8)	26·8% (23·3 to 29·5)	4·6 (4·2 to 4·8)	0·1% (–2·6 to 2·2)	11 189·0 (10 386·5 to 11 664·8)	18·4% (12·8 to 22·8)	144·4 (133·8 to 150·9)
	Other neoplasms		102·9 (80·2 to 122·4)	42·0% (35·6 to 51·7)	1·3 (1·0 to 1·6)	7·4% (2·1 to 15·8)	2425·8 (2024·4 to 2932·1)	32·9% (25·9 to 42·7)	31·1 (25·9 to 37·4)
		Myelodysplastic, myeloproliferative, and other haemopoietic neoplasms	98·8 (76·7 to 118·1)	42·6% (36·2 to 52·2)	1·3 (1·0 to 1·5)	7·1% (1·8 to 15·3)	2189·1 (1820·8 to 2665·5)	33·9% (26·6 to 43·3)	27·9 (23·2 to 33·8)
		Other benign and in- situ neoplasms	4·1 (3·2 to 4·8)	29·6% (17·2 to 44·5)	0·1 (0·0 to 0·1)	15·5% (4·1 to 29·2)	236·8 (186·4 to 277·7)	25·0% (12·7 to 38·6)	3·2 (2·5 to 3·7)
	Cardiovascular diseases		17 790·9 (17 527·1 to 18 042·7)	21·1% (19·7 to 22·6)	233·1 (229·7 to 236·4)	–10·3% (–11·4 to –9·3)	330 172·6 (324 899·3 to 335 159·9)	14·7% (13·3 to 16·2)	4148·0 (4082·0 to 4210·8)
	Rheumatic heart disease		285·5 (266·2 to 303·3)	1·3% (–3·9 to 6·0)	3·7 (3·4 to 3·9)	–21·3% (–25·2 to –17·8)	7492·6 (6926·7 to 8046·7)	–10·2% (–15·4 to –6·2)	94·5 (87·5 to 101·4)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Ischaemic heart disease		8930·4 (8790·7 to 9138·7)	22·3% (20·6 to 23·8)	116·9 (115·1 to 119·7)	–9·7% (–11·0 to –8·7)	164 983·4 (162 168·9 to 168 584·2)	17·3% (15·4 to 19·0)	2065·9 (2030·6 to 2111·7)
	Stroke		6167·3 (6044·3 to 6327·6)	16·6% (14·7 to 18·6)	80·5 (78·9 to 82·6)	–13·6% (–15·0 to –12·1)	113 355·9 (110 957·8 to 116 180·6)	12·1% (9·9 to 14·1)	1422·2 (1392·0 to 1457·7)
		Ischaemic stroke	2747·4 (2657·1 to 2857·6)	21·2% (19·0 to 23·3)	36·6 (35·5 to 38·0)	–11·8% (–13·4 to –10·3)	40 834·1 (39 133·3 to 43 140·9)	16·9% (14·3 to 19·3)	521·8 (500·5 to 550·2)
		Intracerebral haemorrhage	2974·9 (2880·8 to 3072·8)	12·5% (9·6 to 15·1)	38·2 (37·0 to 39·4)	–15·7% (–17·8 to –13·8)	61 562·6 (59 598·2 to 63 531·4)	9·3% (6·5 to 11·8)	764·1 (739·7 to 788·4)
		Subarachnoid haemorrhage	445·0 (417·2 to 492·3)	18·4% (13·4 to 24·6)	5·7 (5·3 to 6·3)	–9·4% (–13·1 to –4·9)	10 959·3 (10 294·3 to 12 264·1)	10·7% (6·8 to 16·5)	136·4 (128·2 to 152·5)
	Hypertensive heart disease		925·7 (681·4 to 994·9)	46·6% (26·3 to 59·3)	12·3 (9·0 to 13·2)	7·5% (–7·3 to 16·3)	15 135·2 (11 349·8 to 16 311·7)	35·7% (19·1 to 47·9)	191·5 (143·3 to 206·2)
	Non-rheumatic valvular heart disease		144·9 (121·8 to 150·4)	31·8% (27·7 to 34·7)	2·0 (1·6 to 2·0)	–5·3% (–7·9 to –3·2)	2168·4 (1980·3 to 2322·7)	21·8% (18·6 to 25·0)	27·9 (25·4 to 29·6)
		Non-rheumatic calcific aortic valve disease	102·7 (82·7 to 108·0)	40·0% (33·0 to 44·9)	1·4 (1·1 to 1·5)	–1·0% (–5·6 to 2·2)	1345·1 (1185·5 to 1432·5)	30·4% (25·1 to 35·3)	17·5 (15·3 to 18·6)
		Non-rheumatic degenerative mitral valve disease	35·7 (30·5 to 42·5)	16·4% (11·0 to 23·4)	0·5 (0·4 to 0·6)	–14·0% (–18·1 to –8·6)	683·6 (592·6 to 787·0)	10·3% (4·9 to 16·2)	8·7 (7·5 to 10·0)
		Other non-rheumatic valve diseases	6·4 (4·9 to 8·7)	9·7% (–4·1 to 42·2)	0·1 (0·1 to 0·1)	–17·8% (–28·5 to 8·0)	139·7 (105·8 to 187·5)	8·1% (–2·4 to 27·6)	1·8 (1·4 to 2·4)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Cardiomyopathy and myocarditis		368·5 (341·9 to 386·9)	8·1% (3·8 to 18·2)	4·8 (4·5 to 5·0)	–16·6% (–19·8 to –9·4)	9623·3 (8867·5 to 10 208·8)	–5·1% (–9·6 to 5·5)	122·4 (113·0 to 129·7)
		Myocarditis	46·5 (39·7 to 51·8)	14·4% (5·6 to 29·7)	0·6 (0·5 to 0·7)	–13·3% (–20·4 to –0·1)	1259·3 (1100·1 to 1415·5)	–0·3% (–6·9 to 7·6)	16·6 (14·5 to 18·5)
		Alcoholic cardiomyopathy	88·9 (80·9 to 96·3)	–25·3% (–29·5 to –8·3)	1·1 (1·0 to 1·2)	–40·5% (–43·7 to –27·6)	2849·2 (2599·0 to 3073·1)	–30·7% (–34·7 to –12·1)	34·7 (31·7 to 37·5)
		Other cardiomyopathy	233·2 (213·7 to 248·3)	28·5% (24·5 to 32·4)	3·1 (2·8 to 3·3)	–3·6% (–6·7 to –0·7)	5514·8 (4946·7 to 5992·9)	15·7% (10·9 to 19·9)	71·1 (64·0 to 77·0)
	Atrial fibrillation and flutter		287·2 (276·4 to 304·8)	47·8% (45·4 to 50·6)	4·0 (3·9 to 4·2)	2·6% (0·9 to 4·6)	3054·5 (2923·0 to 3235·4)	40·5% (37·9 to 43·4)	40·6 (38·9 to 43·1)
	Aortic aneurysm		167·2 (159·8 to 174·1)	23·7% (19·9 to 27·6)	2·2 (2·1 to 2·3)	–8·5% (–11·2 to –5·8)	3039·9 (2877·2 to 3186·4)	19·0% (14·5 to 23·6)	38·2 (36·2 to 40·0)
	Peripheral vascular disease		70·2 (43·2 to 123·3)	55·7% (31·0 to 74·2)	1·0 (0·6 to 1·7)	10·5% (–6·8 to 24·1)	916·9 (576·9 to 1540·0)	48·3% (25·0 to 65·6)	11·8 (7·4 to 20·0)
	Endocarditis		83·4 (74·3 to 94·3)	32·2% (25·2 to 36·8)	1·1 (1·0 to 1·2)	1·0% (–4·0 to 5·0)	2174·5 (2033·2 to 2373·0)	16·9% (8·9 to 22·2)	28·3 (26·4 to 30·9)
	Other cardiovascular and circulatory diseases		360·7 (338·1 to 392·9)	21·9% (17·9 to 24·8)	4·7 (4·4 to 5·1)	–7·9% (–10·9 to –5·9)	8228·0 (7681·4 to 9061·9)	12·6% (9·5 to 15·7)	104·7 (97·8 to 115·2)
	Chronic respiratory diseases		3914·2 (3790·6 to 4044·8)	15·8% (12·7 to 19·3)	51·4 (49·7 to 53·1)	–14·2% (–16·5 to –11·5)	68 004·9 (65 869·4 to 70 592·2)	9·7% (7·0 to 13·2)	861·9 (835·4 to 895·0)
	Chronic obstructive pulmonary disease		3197·8 (3029·0 to 3358·9)	17·5% (13·3 to 21·1)	42·2 (40·0 to 44·2)	–13·6% (–16·5 to –11·0)	50 990·0 (47 678·7 to 54 146·9)	13·2% (8·8 to 16·9)	647·3 (605·9 to 686·4)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Pneumoconiosis		21·6 (20·5 to 22·7)	10·7% (5·1 to 16·6)	0·3 (0·3 to 0·3)	–16·7% (–20·8 to –12·4)	426·9 (403·6 to 452·9)	7·9% (1·8 to 14·6)	5·3 (5·0 to 5·6)
		Silicosis	11·3 (10·4 to 12·5)	12·0% (1·2 to 22·8)	0·1 (0·1 to 0·2)	–15·5% (–23·6 to –7·4)	235·7 (210·3 to 258·2)	11·8% (–0·7 to 23·6)	2·9 (2·6 to 3·2)
		Asbestosis	3·4 (2·3 to 3·9)	23·3% (15·1 to 33·9)	0·0 (0·0 to 0·1)	–8·3% (–14·1 to –0·4)	54·6 (38·6 to 65·6)	15·6% (7·4 to 28·5)	0·7 (0·5 to 0·8)
		Coal worker pneumoconiosis	3·2 (2·9 to 4·0)	–2·2% (–12·0 to 11·7)	0·0 (0·0 to 0·1)	–26·6% (–33·8 to –16·7)	58·9 (52·2 to 76·4)	–6·4% (–16·3 to 8·3)	0·7 (0·7 to 1·0)
		Other pneumoconiosis	3·6 (3·1 to 4·5)	8·9% (0·0 to 25·4)	0·0 (0·0 to 0·1)	–17·5% (–24·1 to –5·0)	77·6 (66·1 to 96·4)	4·2% (–3·8 to 19·5)	1·0 (0·8 to 1·2)
	Asthma		495·1 (338·2 to 641·2)	–0·7% (–6·2 to 8·1)	6·3 (4·3 to 8·2)	–23·9% (–28·1 to –17·2)	12 139·9 (8538·5 to 15 576·3)	–7·5% (–11·4 to –1·6)	152·8 (108·3 to 195·8)
	Interstitial lung disease and pulmonary sarcoidosis		147·6 (114·9 to 181·3)	49·8% (39·0 to 58·6)	1·9 (1·5 to 2·4)	11·4% (4·0 to 17·9)	2716·7 (2156·9 to 3371·3)	43·0% (32·1 to 53·4)	34·2 (27·1 to 42·4)
	Other chronic respiratory diseases		52·1 (45·9 to 59·6)	21·3% (14·1 to 34·2)	0·7 (0·6 to 0·8)	–3·2% (–8·7 to 6·7)	1731·4 (1504·5 to 1998·9)	10·8% (3·2 to 24·3)	22·1 (19·3 to 25·5)
	Digestive diseases		2377·7 (2295·1 to 2518·0)	15·3% (12·1 to 19·7)	30·3 (29·2 to 32·1)	–10·7% (–13·1 to –7·3)	65 348·4 (62 343·9 to 69 371·3)	7·5% (4·2 to 11·9)	819·8 (781·7 to 869·7)
	Cirrhosis and other chronic liver diseases		1322·9 (1268·2 to 1449·1)	15·0% (8·7 to 21·5)	16·5 (15·8 to 18·1)	–9·7% (–14·7 to –4·6)	39 652·4 (37 985·2 to 43 624·9)	8·9% (3·4 to 14·4)	488·9 (468·0 to 537·5)
		Cirrhosis and other chronic liver diseases due to hepatitis B	384·0 (349·1 to 441·7)	8·6% (1·1 to 17·3)	4·8 (4·3 to 5·5)	–14·3% (–20·2 to –7·3)	11 721·5 (10 648·0 to 13 431·7)	3·4% (–3·3 to 10·7)	144·1 (130·8 to 165·3)
		Cirrhosis and other chronic liver diseases due to hepatitis C	342·2 (312·6 to 381·1)	17·4% (11·3 to 23·0)	4·2 (3·9 to 4·7)	–8·4% (–13·0 to –3·9)	9980·1 (9074·7 to 11 116·9)	12·2% (6·8 to 17·3)	121·9 (111·0 to 135·8)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Cirrhosis and other chronic liver diseases due to alcohol use	332.3 (303.0 to 373.3)	16.9% (11.2 to 23.7)	4.1 (3.7 to 4.6)	–8.8% (–13.2 to –3.4)	9785.4 (8919.3 to 10 962.1)	12.3% (7.1 to 18.3)	119.0 (108.6 to 133.5)
		Cirrhosis due to NASH	118.0 (108.6 to 128.6)	27.6% (21.2 to 33.3)	1.5 (1.3 to 1.6)	–1.4% (–6.3 to 3.1)	3285.5 (3011.9 to 3586.8)	22.2% (16.6 to 27.2)	40.0 (36.6 to 43.6)
		Cirrhosis and other chronic liver diseases due to other causes	146.4 (130.9 to 164.6)	14.2% (8.2 to 20.2)	1.9 (1.7 to 2.1)	–8.6% (–13.4 to –3.8)	4880.0 (4392.5 to 5457.1)	2.1% (–4.3 to 10.7)	63.9 (57.5 to 71.4)
	Upper digestive system diseases		292.1 (279.7 to 312.3)	2.9% (–1.3 to 8.6)	3.8 (3.6 to 4.0)	–21.6% (–24.8 to –17.3)	6789.9 (6413.1 to 7259.0)	–4.5% (–9.5 to 1.8)	85.2 (80.4 to 91.2)
		Peptic ulcer disease	240.3 (229.4 to 258.8)	0.6% (–3.6 to 5.6)	3.1 (3.0 to 3.3)	–23.5% (–26.6 to –19.7)	5513.3 (5202.4 to 5947.8)	–6.8% (–11.4 to –1.5)	69.1 (65.1 to 74.7)
		Gastritis and duodenitis	51.8 (43.0 to 56.9)	15.5% (7.5 to 28.9)	0.7 (0.6 to 0.7)	–11.7% (–17.6 to –2.2)	1276.6 (1047.1 to 1419.7)	6.8% (–3.1 to 22.4)	16.1 (13.2 to 17.9)
	Appendicitis		43.9 (40.2 to 47.5)	1.8% (–4.0 to 9.6)	0.6 (0.5 to 0.6)	–17.0% (–21.5 to –10.7)	1633.2 (1473.2 to 1772.7)	–8.7% (–16.7 to 0.6)	21.4 (19.3 to 23.3)
	Paralytic ileus and intestinal obstruction		240.5 (198.7 to 261.6)	21.1% (14.4 to 29.0)	3.2 (2.7 to 3.5)	–5.8% (–11.0 to 0.3)	7245.9 (5866.8 to 7980.6)	6.5% (–3.1 to 15.5)	97.0 (78.9 to 106.8)
	Inguinal, femoral, and abdominal hernia		44.2 (38.6 to 50.0)	21.7% (16.2 to 28.4)	0.6 (0.5 to 0.7)	–8.9% (–12.9 to –4.2)	914.3 (792.8 to 1021.9)	12.1% (4.5 to 20.4)	11.7 (10.1 to 13.1)
	Inflammatory bowel disease		38.6 (31.6 to 41.2)	20.4% (11.5 to 27.2)	0.5 (0.4 to 0.5)	–10.5% (–16.0 to –5.9)	829.7 (711.4 to 900.7)	10.3% (–2.7 to 19.5)	10.7 (9.1 to 11.7)
	Vascular intestinal disorders		96.1 (89.0 to 100.8)	22.6% (17.0 to 28.1)	1.3 (1.2 to 1.3)	–10.2% (–14.2 to –6.2)	1570.1 (1433.3 to 1667.3)	17.6% (10.7 to 24.8)	20.0 (18.3 to 21.3)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Gallbladder and biliary diseases		110·5 (105·5 to 116·6)	28·8% (25·3 to 33·8)	1·5 (1·4 to 1·6)	–5·0% (–7·5 to –1·7)	1983·2 (1863·2 to 2092·0)	18·5% (13·4 to 25·3)	25·4 (23·8 to 26·8)
	Pancreatitis		101·6 (89·5 to 108·3)	20·6% (16·4 to 25·7)	1·3 (1·1 to 1·4)	–5·7% (–9·0 to –1·7)	2890·0 (2537·1 to 3102·9)	13·8% (8·7 to 19·5)	35·8 (31·4 to 38·4)
	Other digestive diseases		87·3 (81·9 to 93·3)	25·4% (18·1 to 32·3)	1·2 (1·1 to 1·2)	–7·1% (–12·1 to –2·4)	1839·7 (1663·9 to 2038·5)	16·4% (5·8 to 27·4)	23·7 (21·5 to 26·3)
	Neurological disorders		3094·2 (3039·6 to 3142·6)	42·1% (40·2 to 43·9)	43·1 (42·3 to 43·7)	0·1% (–1·2 to 1·3)	38 004·5 (37 134·8 to 39 174·6)	26·2% (23·9 to 30·2)	507·6 (496·1 to 523·4)
	Alzheimer's disease and other dementias		2514·6 (2470·5 to 2550·3)	46·2% (43·9 to 48·0)	35·4 (34·8 to 35·9)	0·6% (–0·9 to 1·8)	23 951·1 (23 523·6 to 24 326·8)	38·6% (35·7 to 40·9)	323·7 (317·9 to 328·7)
	Parkinson's disease		340·6 (324·4 to 355·1)	38·3% (33·3 to 41·4)	4·6 (4·4 to 4·8)	0·8% (–2·8 to 3·0)	4361·2 (4182·8 to 4578·7)	33·8% (28·5 to 37·0)	56·9 (54·5 to 59·8)
	Epilepsy		130·2 (117·0 to 150·8)	3·8% (–1·6 to 15·7)	1·7 (1·5 to 2·0)	–10·7% (–15·4 to –0·5)	6232·1 (5709·8 to 7289·7)	–5·5% (–11·6 to 8·3)	82·6 (75·5 to 96·6)
	Multiple sclerosis		20·7 (17·7 to 22·2)	22·4% (8·0 to 27·8)	0·3 (0·2 to 0·3)	–3·9% (–14·5 to 0·4)	628·2 (563·0 to 682·4)	17·1% (4·1 to 24·5)	7·7 (6·9 to 8·3)
	Motor neuron disease		34·1 (32·8 to 37·1)	32·7% (28·0 to 37·0)	0·4 (0·4 to 0·5)	1·2% (–2·4 to 4·5)	828·1 (796·7 to 917·1)	27·2% (22·6 to 31·3)	10·3 (9·9 to 11·4)
	Other neurological disorders		53·9 (51·6 to 59·0)	25·4% (17·8 to 32·3)	0·7 (0·7 to 0·8)	2·0% (–3·9 to 6·8)	2003·8 (1856·8 to 2269·5)	11·4% (3·6 to 21·1)	26·5 (24·3 to 30·1)
	Mental disorders		0·3 (0·3 to 0·4)	19·9% (10·0 to 29·2)	0·0 (0·0 to 0·0)	7·5% (–1·4 to 15·9)	17·5 (15·9 to 19·2)	18·5% (8·8 to 27·5)	0·2 (0·2 to 0·2)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Eating disorders		0·3 (0·3 to 0·4)	19·9% (10·0 to 29·2)	0·0 (0·0 to 0·0)	7·5% (–1·4 to 15·9)	17·5 (15·9 to 19·2)	18·5% (8·8 to 27·5)	0·2 (0·2 to 0·2)
		Anorexia nervosa	0·2 (0·2 to 0·3)	17·6% (7·0 to 27·6)	0·0 (0·0 to 0·0)	5·5% (–4·1 to 14·4)	12·7 (10·9 to 14·1)	15·9% (5·6 to 25·6)	0·2 (0·1 to 0·2)
		Bulimia nervosa	0·1 (0·1 to 0·1)	26·4% (12·9 to 40·5)	0·0 (0·0 to 0·0)	13·5% (1·0 to 26·2)	4·8 (4·0 to 6·7)	25·9% (12·0 to 40·0)	0·1 (0·1 to 0·1)
	Substance use disorders		351·5 (334·1 to 362·7)	23·8% (20·2 to 27·3)	4·3 (4·1 to 4·5)	2·0% (–1·0 to 5·0)	13 597·6 (12 979·5 to 14 033·3)	18·8% (15·3 to 22·4)	168·0 (160·4 to 173·3)
	Alcohol use disorders		184·9 (166·7 to 193·0)	2·7% (–2·2 to 7·7)	2·3 (2·0 to 2·4)	–16·5% (–20·4 to –12·4)	6750·4 (6113·2 to 7082·7)	–2·1% (–7·2 to 3·3)	82·4 (74·7 to 86·5)
	Drug use disorders		166·6 (163·4 to 170·3)	60·2% (56·9 to 63·6)	2·1 (2·0 to 2·1)	34·1% (31·4 to 36·9)	6847·2 (6704·5 to 7004·4)	50·4% (47·0 to 54·0)	85·5 (83·7 to 87·5)
		Opioid use disorders	109·5 (105·7 to 113·6)	77·0% (68·8 to 88·5)	1·4 (1·3 to 1·4)	49·4% (42·5 to 59·2)	4641·2 (4480·6 to 4818·9)	65·0% (57·3 to 75·0)	58·0 (56·1 to 60·3)
		Cocaine use disorders	7·3 (6·6 to 8·1)	42·2% (30·1 to 58·3)	0·1 (0·1 to 0·1)	19·6% (9·2 to 33·0)	311·5 (281·5 to 344·1)	35·6% (24·0 to 51·2)	3·9 (3·5 to 4·3)
		Amphetamine use disorders	4·5 (3·3 to 5·0)	27·2% (0·8 to 41·0)	0·1 (0·0 to 0·1)	8·7% (–14·0 to 20·7)	206·9 (151·6 to 227·8)	21·0% (–3·6 to 34·4)	2·6 (1·9 to 2·8)
		Other drug use disorders	45·3 (42·9 to 48·2)	35·2% (22·8 to 46·1)	0·6 (0·5 to 0·6)	11·3% (1·2 to 19·9)	1687·6 (1589·4 to 1805·9)	25·9% (14·0 to 37·3)	21·0 (19·8 to 22·5)
	Diabetes and kidney diseases		2611·2 (2557·8 to 2667·2)	34·2% (32·0 to 36·2)	33·6 (32·9 to 34·3)	1·3% (–0·3 to 2·7)	58 116·9 (56 801·5 to 59 525·7)	25·1% (23·0 to 27·2)	726·4 (710·0 to 744·4)
	Diabetes mellitus		1369·8 (1340·3 to 1401·9)	34·7% (32·2 to 37·3)	17·5 (17·1 to 17·9)	1·2% (–0·7 to 3·1)	29 300·2 (28 711·5 to 29 950·1)	29·9% (27·2 to 32·4)	363·1 (355·7 to 371·2)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Type 1 diabetes mellitus	345.5 (319.3 to 371.1)	15.1% (10.5 to 19.0)	4.3 (4.0 to 4.7)	–11.0% (–14.6 to –7.8)	9477.3 (8944.6 to 10 079.9)	11.1% (7.2 to 14.3)	117.3 (110.8 to 124.6)
		Type 2 diabetes mellitus	1024.3 (985.5 to 1066.8)	43.0% (40.4 to 45.8)	13.2 (12.7 to 13.7)	5.9% (4.1 to 8.0)	19 822.9 (19 013.8 to 20 687.8)	41.3% (38.3 to 44.4)	245.8 (235.8 to 256.5)
	Chronic kidney disease		1230.2 (1195.1 to 1258.8)	33.7% (30.5 to 36.1)	15.9 (15.5 to 16.3)	1.5% (–0.9 to 3.2)	28 508.5 (27 610.2 to 29 314.0)	21.0% (18.2 to 23.5)	359.4 (348.2 to 369.6)
		Chronic kidney disease due to type 1 diabetes mellitus	77.3 (62.4 to 95.2)	23.2% (19.0 to 27.4)	0.9 (0.8 to 1.2)	–1.2% (–4.0 to 1.2)	2622.0 (2121.7 to 3205.5)	17.8% (13.6 to 22.3)	31.9 (25.9 to 38.9)
		Chronic kidney disease due to type 2 diabetes mellitus	349.0 (306.8 to 395.9)	40.5% (36.4 to 43.6)	4.5 (4.0 to 5.1)	4.2% (1.4 to 6.2)	6671.9 (5825.5 to 7625.9)	35.4% (31.0 to 38.7)	82.8 (72.4 to 94.5)
		Chronic kidney disease due to hypertension	347.4 (304.6 to 391.5)	41.4% (37.4 to 44.2)	4.6 (4.0 to 5.2)	3.2% (0.4 to 5.2)	5954.8 (5175.1 to 6741.9)	33.4% (29.3 to 36.5)	75.2 (65.4 to 84.9)
		Chronic kidney disease due to glomerulonephritis	189.7 (165.2 to 217.3)	25.5% (22.1 to 28.8)	2.4 (2.1 to 2.8)	–1.3% (–3.2 to 0.7)	5554.9 (4929.1 to 6250.8)	12.7% (9.6 to 16.1)	70.6 (62.8 to 79.4)
		Chronic kidney disease due to other and unspecified causes	266.8 (232.8 to 304.0)	25.9% (22.4 to 29.4)	3.4 (3.0 to 3.9)	–1.4% (–3.7 to 0.6)	7704.8 (6794.9 to 8614.8)	10.0% (6.8 to 13.4)	98.9 (87.4 to 110.0)
	Acute glomerulonephritis		11.2 (10.5 to 12.1)	14.7% (8.7 to 22.3)	0.1 (0.1 to 0.2)	–9.5% (–14.5 to –3.5)	308.2 (282.4 to 336.8)	–5.5% (–10.4 to 2.2)	3.9 (3.6 to 4.3)
	Skin and subcutaneous diseases		100.3 (65.3 to 131.7)	42.3% (34.9 to 52.0)	1.3 (0.9 to 1.7)	8.1% (2.7 to 16.5)	2517.9 (1703.3 to 3283.8)	26.1% (18.6 to 35.7)	33.1 (22.4 to 43.2)
	Bacterial skin diseases		76.0 (48.7 to 95.6)	45.5% (36.8 to 54.9)	1.0 (0.6 to 1.3)	12.7% (6.0 to 20.7)	2096.6 (1378.0 to 2691.9)	26.4% (18.0 to 36.9)	27.6 (18.2 to 35.6)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Cellulitis	18·9 (10·3 to 26·0)	57·0% (45·8 to 67·1)	0·2 (0·1 to 0·3)	19·6% (9·8 to 28·2)	480·1 (264·6 to 640·2)	38·3% (30·8 to 50·4)	6·2 (3·4 to 8·3)
		Pyoderma	57·1 (35·8 to 70·8)	42·1% (32·4 to 52·4)	0·8 (0·5 to 0·9)	10·5% (3·2 to 19·0)	1616·4 (1051·6 to 2136·7)	23·3% (14·3 to 35·0)	21·5 (14·1 to 28·8)
	Decubitus ulcer		20·3 (13·2 to 30·6)	32·4% (22·9 to 51·0)	0·3 (0·2 to 0·4)	–5·1% (–12·2 to 9·2)	321·7 (211·2 to 471·5)	26·2% (17·9 to 42·5)	4·2 (2·7 to 6·1)
	Other skin and subcutaneous diseases		3·9 (2·6 to 7·2)	35·8% (26·6 to 49·6)	0·1 (0·0 to 0·1)	3·3% (–3·5 to 14·4)	99·6 (69·4 to 165·8)	19·1% (10·8 to 34·1)	1·3 (0·9 to 2·2)
	Musculoskeletal disorders		121·3 (105·6 to 126·2)	30·9% (25·1 to 35·1)	1·6 (1·4 to 1·6)	–0·1% (–4·4 to 3·2)	2842·7 (2440·7 to 2953·1)	19·6% (13·7 to 23·2)	35·9 (30·8 to 37·3)
	Rheumatoid arthritis		47·3 (39·0 to 51·2)	25·8% (16·2 to 31·9)	0·6 (0·5 to 0·7)	–5·9% (–12·9 to –1·2)	866·0 (707·8 to 941·4)	17·9% (8·6 to 23·3)	10·9 (8·9 to 11·8)
	Other musculoskeletal disorders		74·0 (66·1 to 78·7)	34·4% (30·2 to 38·8)	1·0 (0·9 to 1·0)	3·9% (0·9 to 7·5)	1976·6 (1730·3 to 2089·1)	20·3% (15·6 to 24·0)	25·0 (21·9 to 26·4)
	Other non-communicable diseases		1153·3 (1101·8 to 1208·3)	0·8% (–3·9 to 4·0)	16·3 (15·5 to 17·1)	–11·2% (–15·3 to –8·5)	68 240·8 (64 835·4 to 72 452·1)	–10·6% (–15·8 to –6·9)	993·0 (941·3 to 1054·3)
	Congenital anomalies		584·9 (556·3 to 618·3)	–14·3% (–21·1 to –10·1)	8·7 (8·2 to 9·2)	–18·2% (–24·7 to –14·1)	48 860·4 (46 405·7 to 51 687·3)	–15·3% (–22·0 to –11·0)	729·4 (692·5 to 771·7)
		Neural tube defects	61·7 (46·7 to 83·7)	–13·1% (–24·5 to –1·0)	0·9 (0·7 to 1·3)	–16·5% (–27·6 to –4·8)	5317·5 (4017·1 to 7217·5)	–13·4% (–24·8 to –1·4)	80·0 (60·4 to 108·6)
		Congenital heart anomalies	261·2 (216·6 to 308·2)	–17·9% (–24·6 to –9·8)	3·9 (3·2 to 4·6)	–21·8% (–28·1 to –14·1)	21 634·4 (17 770·6 to 25 604·8)	–18·9% (–25·5 to –10·8)	321·7 (263·6 to 381·4)
		Orofacial clefts	3·8 (1·5 to 8·8)	–40·0% (–54·5 to –22·5)	0·1 (0·0 to 0·1)	–41·9% (–55·9 to –25·1)	331·3 (130·1 to 770·5)	–40·0% (–54·5 to –22·7)	5·0 (2·0 to 11·7)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Down syndrome	26·1 (21·3 to 35·1)	3·1% (–7·4 to 17·4)	0·4 (0·3 to 0·5)	–5·2% (–14·2 to 7·0)	1906·1 (1481·7 to 2707·9)	–1·4% (–11·5 to 13·9)	27·7 (21·3 to 39·8)
		Other chromosomal abnormalities	17·9 (12·0 to 26·3)	4·6% (–6·3 to 18·2)	0·3 (0·2 to 0·4)	0·3% (–10·1 to 13·2)	1507·9 (1012·2 to 2233·3)	3·9% (–6·9 to 17·4)	22·6 (15·1 to 33·5)
		Congenital musculoskeletal and limb anomalies	11·0 (8·6 to 14·0)	–8·7% (–17·3 to 0·0)	0·2 (0·1 to 0·2)	–12·8% (–20·9 to –4·5)	912·2 (708·9 to 1172·9)	–9·8% (–18·2 to –1·0)	13·6 (10·6 to 17·5)
		Urogenital congenital anomalies	14·1 (10·3 to 16·9)	–2·5% (–11·8 to 9·2)	0·2 (0·1 to 0·2)	–8·5% (–17·1 to 2·1)	1105·8 (781·3 to 1347·8)	–5·5% (–14·6 to 6·3)	16·4 (11·5 to 20·0)
		Digestive congenital anomalies	50·8 (37·7 to 71·8)	–16·2% (–27·1 to –6·4)	0·8 (0·6 to 1·1)	–19·3% (–29·8 to –9·8)	4398·7 (3253·9 to 6229·0)	–16·5% (–27·3 to –6·7)	66·3 (49·0 to 93·9)
		Other congenital anomalies	138·3 (102·3 to 175·6)	–12·4% (–20·1 to –0·5)	2·1 (1·5 to 2·6)	–15·9% (–23·3 to –4·5)	11 746·6 (8613·3 to 14 951·0)	–13·0% (–20·7 to –1·1)	176·1 (128·8 to 224·2)
	Urinary diseases and male infertility		271·2 (263·9 to 282·2)	39·6% (34·9 to 43·4)	3·6 (3·5 to 3·7)	5·7% (2·2 to 8·5)	6255·2 (6044·8 to 6542·1)	20·8% (15·5 to 24·9)	81·1 (78·3 to 84·8)
		Urinary tract infections	206·4 (197·9 to 223·2)	48·3% (42·9 to 53·5)	2·7 (2·6 to 3·0)	10·9% (7·2 to 14·5)	4522·3 (4285·2 to 5016·3)	31·4% (24·4 to 38·8)	58·4 (55·2 to 65·0)
		Urolithiasis	12·3 (10·5 to 15·7)	30·4% (19·0 to 49·4)	0·2 (0·1 to 0·2)	–1·2% (–9·7 to 12·9)	255·1 (216·0 to 323·5)	19·6% (9·7 to 36·9)	3·2 (2·7 to 4·0)
		Other urinary diseases	52·5 (42·3 to 58·0)	15·0% (8·0 to 25·5)	0·7 (0·6 to 0·8)	–9·9% (–15·3 to –2·2)	1477·8 (1172·2 to 1660·2)	–3·0% (–9·6 to 6·4)	19·4 (15·4 to 21·9)
	Gynaecological diseases		8·2 (7·4 to 8·7)	19·1% (5·1 to 30·0)	0·1 (0·1 to 0·1)	–2·6% (–13·6 to 6·0)	292·9 (272·6 to 318·7)	9·2% (–2·8 to 20·6)	3·7 (3·4 to 4·0)
		Uterine fibroids	2·4 (1·6 to 3·0)	33·3% (6·7 to 54·6)	0·0 (0·0 to 0·0)	8·1% (–14·9 to 24·7)	74·2 (52·7 to 95·5)	13·0% (–4·2 to 31·6)	0·9 (0·6 to 1·2)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Polycystic ovarian syndrome	0·0 (0·0 to 0·0)	12·9% (–12·8 to 50·4)	0·0 (0·0 to 0·0)	1·0% (–22·5 to 34·8)	0·7 (0·1 to 1·5)	10·1% (–15·8 to 51·2)	0·0 (0·0 to 0·0)
		Endometriosis	0·2 (0·1 to 0·2)	11·8% (–12·4 to 45·5)	0·0 (0·0 to 0·0)	–3·2% (–23·8 to 25·5)	7·7 (3·2 to 12·0)	10·4% (–12·9 to 41·7)	0·1 (0·0 to 0·1)
		Genital prolapse	0·6 (0·3 to 0·9)	0·6% (–15·4 to 16·1)	0·0 (0·0 to 0·0)	–24·1% (–36·0 to –13·0)	14·5 (6·8 to 20·1)	–4·4% (–18·4 to 10·4)	0·2 (0·1 to 0·2)
		Other gynaecological diseases	5·0 (4·1 to 5·6)	16·0% (4·1 to 27·9)	0·1 (0·1 to 0·1)	–3·6% (–12·2 to 5·9)	195·8 (163·0 to 228·9)	8·9% (–2·9 to 20·6)	2·5 (2·1 to 2·9)
	Haemoglobinopathies and haemolytic anaemias		104·6 (82·0 to 132·2)	5·8% (–1·4 to 13·4)	1·4 (1·1 to 1·8)	–11·3% (–17·6 to –4·8)	4831·6 (3643·1 to 6268·9)	–1·8% (–13·1 to 9·4)	66·6 (50·0 to 86·2)
		Thalassaemias	7·2 (6·0 to 8·4)	–23·7% (–32·6 to –12·7)	0·1 (0·1 to 0·1)	–27·9% (–36·5 to –17·2)	564·7 (474·8 to 667·6)	–24·6% (–33·9 to –13·2)	8·2 (6·9 to 9·7)
		Sickle cell disorders	38·4 (24·0 to 54·8)	3·7% (–11·6 to 17·7)	0·5 (0·3 to 0·8)	–3·1% (–17·6 to 10·3)	2796·4 (1747·3 to 3913·6)	2·1% (–13·7 to 17·3)	39·7 (24·8 to 55·3)
		G6PD deficiency	16·7 (12·1 to 22·5)	11·8% (4·7 to 19·6)	0·2 (0·2 to 0·3)	–7·1% (–12·1 to –1·0)	692·6 (522·0 to 896·1)	4·4% (–2·5 to 12·3)	8·8 (6·7 to 11·4)
		Other haemoglobinopathies and haemolytic anaemias	42·2 (35·1 to 49·2)	13·0% (9·3 to 16·5)	0·6 (0·5 to 0·6)	–16·1% (–18·7 to –13·4)	777·8 (634·5 to 917·2)	1·3% (–2·2 to 4·8)	9·9 (8·1 to 11·7)
	Endocrine, metabolic, blood, and immune disorders		144·5 (115·1 to 152·3)	28·2% (19·7 to 33·3)	1·9 (1·5 to 2·0)	0·8% (–5·0 to 4·4)	4506·4 (3762·3 to 4919·9)	10·4% (2·7 to 16·9)	59·7 (50·0 to 65·5)
	Sudden infant death syndrome		40·0 (18·0 to 77·0)	–17·3% (–28·6 to –1·4)	0·6 (0·3 to 1·2)	–20·2% (–31·2 to –4·9)	3494·3 (1570·1 to 6734·0)	–17·3% (–28·6 to –1·4)	52·7 (23·7 to 101·5)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
Injuries			4484·7 (4332·0 to 4585·6)	2·3% (0·5 to 4·0)	57·9 (55·9 to 59·2)	–13·7% (–15·1 to –12·2)	195 231·1 (188 807·7 to 199 825·5)	–6·4% (–7·8 to –4·8)	2548·3 (2461·9 to 2609·6)
	Transport injuries		1335·0 (1289·1 to 1369·5)	–3·1% (–6·0 to –0·6)	17·0 (16·4 to 17·4)	–17·0% (–19·5 to –14·9)	61 937·8 (60 031·2 to 63 736·5)	–9·6% (–11·8 to –7·3)	800·5 (775·9 to 823·3)
	Road injuries		1243·1 (1191·9 to 1276·9)	–3·2% (–6·3 to –0·5)	15·8 (15·2 to 16·3)	–17·1% (–19·7 to –14·9)	57 638·4 (55 500·8 to 59 369·2)	–9·7% (–12·0 to –7·3)	745·0 (718·1 to 767·4)
		Pedestrian road injuries	486·2 (459·7 to 535·0)	–6·4% (–11·7 to –2·1)	6·2 (5·9 to 6·8)	–21·4% (–25·5 to –17·9)	20 850·8 (19 596·0 to 23 164·4)	–14·8% (–18·7 to –11·0)	270·4 (253·9 to 300·8)
		Cyclist road injuries	68·9 (59·2 to 76·2)	9·1% (1·8 to 16·4)	0·9 (0·7 to 1·0)	–8·8% (–14·8 to –2·5)	2853·5 (2471·6 to 3209·0)	1·0% (–5·7 to 8·3)	36·3 (31·5 to 41·0)
		Motorcyclist road injuries	225·7 (196·1 to 238·6)	–0·6% (–8·9 to 5·2)	2·9 (2·5 to 3·0)	–12·4% (–19·5 to –7·3)	11 416·3 (9969·6 to 12 098·0)	–5·7% (–12·5 to –0·5)	146·2 (127·5 to 154·9)
		Motor vehicle road injuries	451·1 (423·4 to 472·9)	–2·5% (–6·2 to 1·3)	5·8 (5·4 to 6·0)	–15·6% (–18·6 to –12·2)	22 004·1 (20 639·8 to 23 130·9)	–7·8% (–10·4 to –3·0)	285·3 (267·6 to 299·7)
		Other road injuries	11·2 (9·9 to 12·8)	–5·5% (–11·0 to 16·1)	0·1 (0·1 to 0·2)	–19·4% (–24·1 to –1·3)	513·8 (454·1 to 583·4)	–11·7% (–17·3 to 10·6)	6·7 (5·9 to 7·6)
	Other transport injuries		91·9 (84·5 to 107·2)	–1·5% (–6·2 to 3·7)	1·2 (1·1 to 1·4)	–15·5% (–19·5 to –10·9)	4299·4 (3919·6 to 5048·3)	–7·8% (–12·6 to –2·4)	55·4 (50·5 to 65·0)
	Unintentional injuries		1804·9 (1695·7 to 1872·0)	2·9% (0·5 to 6·0)	23·8 (22·4 to 24·7)	–15·3% (–17·3 to –12·8)	69 430·5 (64 685·1 to 72 366·8)	–12·8% (–15·0 to –9·6)	928·8 (865·6 to 969·3)
	Falls		695·8 (644·9 to 741·7)	27·4% (21·2 to 35·6)	9·2 (8·5 to 9·8)	–2·8% (–7·4 to 3·4)	16 688·1 (15 101·9 to 17 636·8)	10·1% (4·8 to 17·2)	216·6 (196·4 to 228·6)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Drowning		295·2 (284·5 to 306·2)	–17·2% (–19·8 to –14·1)	4·0 (3·8 to 4·1)	–27·3% (–29·6 to –24·5)	16 563·3 (15 784·2 to 17 350·0)	–26·1% (–29·0 to –22·4)	228·3 (217·2 to 239·7)
	Fire heat and hot substances		120·6 (101·6 to 129·4)	–7·9% (–10·9 to –1·2)	1·6 (1·3 to 1·7)	–22·9% (–25·4 to –17·3)	5286·3 (4308·9 to 5836·4)	–16·5% (–21·0 to –7·3)	71·0 (57·8 to 78·6)
	Poisonings		72·4 (52·7 to 79·4)	–6·8% (–16·1 to 2·9)	0·9 (0·7 to 1·0)	–20·8% (–28·4 to –12·5)	3321·7 (2454·1 to 3669·2)	–14·6% (–22·7 to –3·8)	44·1 (32·7 to 48·8)
		Poisoning by carbon monoxide	35·5 (25·7 to 38·8)	–12·5% (–22·4 to –5·0)	0·5 (0·3 to 0·5)	–26·6% (–34·8 to –20·3)	1462·4 (1073·0 to 1613·6)	–19·1% (–27·2 to –11·8)	18·9 (13·8 to 20·9)
		Poisoning by other means	36·9 (26·8 to 41·0)	–0·5% (–10·1 to 11·9)	0·5 (0·4 to 0·5)	–14·4% (–22·4 to –3·9)	1859·3 (1385·8 to 2072·9)	–10·7% (–19·6 to 3·3)	25·2 (19·0 to 28·1)
	Exposure to mechanical forces		136·5 (117·6 to 143·2)	–6·7% (–9·8 to –3·7)	1·8 (1·5 to 1·8)	–20·3% (–22·9 to –17·8)	6385·5 (5500·4 to 6710·8)	–13·8% (–16·6 to –10·8)	84·0 (72·3 to 88·3)
		Unintentional firearm injuries	22·6 (21·1 to 25·8)	–2·9% (–7·5 to 2·8)	0·3 (0·3 to 0·3)	–16·4% (–20·3 to –11·5)	1094·5 (1013·5 to 1275·4)	–7·4% (–12·2 to –1·3)	14·4 (13·3 to 16·9)
		Other exposure to mechanical forces	113·9 (94·7 to 120·8)	–7·4% (–10·6 to –4·1)	1·5 (1·2 to 1·6)	–21·0% (–23·7 to –18·3)	5291·0 (4401·1 to 5626·1)	–15·0% (–18·0 to –11·7)	69·6 (57·8 to 74·0)
	Adverse effects of medical treatment		121·6 (103·6 to 137·6)	16·6% (12·0 to 20·9)	1·6 (1·4 to 1·8)	–6·2% (–10·0 to –2·5)	4363·9 (3619·9 to 5234·0)	4·0% (–1·2 to 11·0)	58·1 (48·0 to 70·7)
	Animal contact		81·1 (44·9 to 94·0)	–1·4% (–6·8 to 6·2)	1·1 (0·6 to 1·2)	–16·0% (–20·5 to –9·6)	3911·9 (2167·6 to 4585·6)	–9·5% (–15·8 to 0·2)	52·4 (29·0 to 61·8)
		Venomous animal contact	70·9 (37·0 to 83·8)	–1·3% (–7·5 to 6·2)	0·9 (0·5 to 1·1)	–16·0% (–21·0 to –9·7)	3407·7 (1758·4 to 4087·5)	–9·7% (–16·4 to –0·7)	45·5 (23·4 to 54·9)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
		Non-venomous animal contact	10·1 (7·1 to 14·4)	–1·6% (–15·3 to 10·2)	0·1 (0·1 to 0·2)	–16·1% (–27·4 to –6·2)	504·2 (335·8 to 750·1)	–7·9% (–26·1 to 6·5)	6·9 (4·5 to 10·3)
	Foreign body		124·1 (119·3 to 130·0)	1·7% (–1·9 to 4·8)	1·7 (1·6 to 1·8)	–14·1% (–17·0 to –11·6)	5907·0 (5566·3 to 6301·2)	–12·4% (–16·4 to –8·3)	83·3 (78·3 to 88·9)
		Pulmonary aspiration and foreign body in airway	115·7 (111·4 to 121·3)	1·9% (–1·9 to 5·0)	1·6 (1·5 to 1·7)	–13·9% (–17·0 to –11·4)	5526·1 (5212·6 to 5910·0)	–12·2% (–16·6 to –8·0)	78·1 (73·5 to 83·7)
		Foreign body in other body part	8·4 (7·5 to 10·3)	–0·5% (–6·9 to 7·1)	0·1 (0·1 to 0·1)	–15·8% (–20·8 to –10·0)	381·0 (326·2 to 474·4)	–14·4% (–21·1 to –6·2)	5·2 (4·4 to 6·5)
	Environmental heat and cold exposure		53·3 (36·8 to 59·2)	–13·2% (–22·4 to –8·4)	0·7 (0·5 to 0·8)	–29·4% (–37·1 to –25·4)	1845·6 (1246·6 to 2066·2)	–21·4% (–28·8 to –17·5)	23·7 (15·8 to 26·7)
	Exposure to forces of nature		9·6 (8·7 to 11·0)	–38·0% (–43·9 to –28·9)	0·1 (0·1 to 0·1)	–45·8% (–50·8 to –37·9)	477·6 (438·4 to 544·3)	–45·0% (–49·4 to –37·3)	6·3 (5·8 to 7·2)
	Other unintentional injuries		94·7 (91·9 to 98·3)	–14·5% (–16·7 to –12·1)	1·2 (1·2 to 1·3)	–25·8% (–27·6 to –23·8)	4679·6 (4519·4 to 4888·2)	–20·7% (–22·9 to –18·1)	60·9 (58·8 to 63·7)
	Self-harm and interpersonal violence		1344·8 (1283·1 to 1380·4)	7·3% (4·6 to 9·7)	17·1 (16·3 to 17·5)	–7·6% (–9·9 to –5·5)	63 862·9 (61 029·9 to 65 755·7)	5·4% (2·8 to 7·7)	819·0 (782·2 to 843·4)
	Self-harm		793·8 (743·5 to 819·7)	1·1% (–2·6 to 3·7)	10·0 (9·4 to 10·3)	–14·8% (–18·0 to –12·6)	33 577·2 (31 449·3 to 34 719·1)	–3·4% (–7·0 to –0·9)	423·6 (396·9 to 438·2)
		Self-harm by firearm	63·8 (54·6 to 78·6)	6·8% (2·3 to 10·8)	0·8 (0·7 to 1·0)	–10·3% (–13·9 to –7·2)	2653·6 (2241·9 to 3288·1)	0·9% (–3·5 to 5·5)	33·5 (28·2 to 41·6)
		Self-harm by other specified means	730·0 (678·5 to 754·9)	0·6% (–3·2 to 3·4)	9·2 (8·5 to 9·5)	–15·2% (–18·4 to –12·8)	30 923·6 (28 832·4 to 32 098·2)	–3·7% (–7·5 to –1·1)	390·1 (363·6 to 405·1)

			All-age deaths (thousands)		Age-standardised death rate (per 100 000)		All-age YLLs (thousands)		Age-stan rate (per
			2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017	Percentage change, 2007–17	2017
	Interpersonal violence		405·3 (365·2 to 431·7)	0·5% (–2·0 to 3·2)	5·2 (4·7 to 5·5)	–11·1% (–13·3 [*] to –8·7)	21 439·8 (19 275·8 to 22 799·8)	–1·6% (–4·4 to 1·3)	276·8 (248·4 to 294·2)
		Assault by firearm	174·4 (147·9 to 188·9)	7·5% (4·3 [*] to 10·8)	2·2 (1·9 to 2·4)	–3·6% (–6·5 [*] to –0·5)	9541·2 (8106·2 to 10 291·7)	5·4% (2·1 [*] to 9·0)	122·9 (104·3 to 132·4)
		Assault by sharp object	91·4 (74·4 to 111·2)	–11·5% (–15·3 [*] to –6·0)	1·2 (0·9 to 1·4)	–22·3% (–25·6 [*] to –17·6)	4634·5 (3747·0 to 5648·9)	–13·9% (–17·6 [*] to –8·5)	59·2 (47·8 to 72·1)
		Assault by other means	139·5 (123·6 to 164·4)	1·3% (–3·4 to 5·6)	1·8 (1·6 to 2·1)	–11·5% (–15·4 [*] to –7·6)	7264·1 (6400·8 to 8583·0)	–1·3% (–5·4 to 3·6)	94·7 (83·3 to 111·5)
	Conflict and terrorism		129·7 (118·1 to 143·2)	118·0% (88·8 to 148·6)	1·7 (1·6 to 1·9)	98·4% (72·4 to 126·1)	7966·6 (7244·5 to 8855·9)	113·5% (84·5 to 146·8)	107·3 (97·6 to 119·1)
	Executions and police conflict		16·0 (15·7 to 16·3)	203·9% (186·9 to 220·9)	0·2 (0·2 to 0·2)	172·4% (156·8 [*] to 187·6)	879·3 (862·3 to 898·1)	202·1% (184·8 to 219·8)	11·4 (11·2 to 11·7)

Data in parentheses are 95% uncertainty intervals. G6PD=glucose-6-phosphate dehydrogenase. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. *H influenzae*=*Haemophilus influenzae*. NASH=non-alcoholic steatohepatitis. YLL=years of life lost.

* Percentage changes that are statistically significant.